RARECast
Podcast autorstwa RARECast - Czwartki
548 Odcinki
-
Navigating the Challenges of Rare Disease Drug Development
Opublikowany: 31.05.2017 -
Accelerating Rare Disease Drug Discovery
Opublikowany: 24.05.2017 -
Experimental Rare Disease Therapy Wins New FDA Reg Med Designation
Opublikowany: 17.05.2017 -
How Rare Disease Patients Can Get their Voices Heard in Drug Discovery and Development
Opublikowany: 10.05.2017 -
One Patient's Difficult Road to a Rare Diagnosis
Opublikowany: 3.05.2017 -
How Researchers Diagnosed Four Patients with a Never-Before-Identified Rare Disease in a Day
Opublikowany: 26.04.2017 -
Stem Cell Gene Therapy Restores Immune System in Kids with SCID
Opublikowany: 19.04.2017 -
Rare Disease Advocates Push for Incentives to Drugmakers Pulled from Cures Act
Opublikowany: 12.04.2017 -
Non-Profit Drug Company Seeks to Advance Rare Disease Therapies
Opublikowany: 5.04.2017 -
Innovative Collaboration Model Drives Treatment for Rare Disease
Opublikowany: 29.03.2017 -
Girl with Rare Disease Inspires Search for Bone Marrow Donors
Opublikowany: 22.03.2017 -
A Quest for Tribe: Searching for Others with the Same Ultra-Rare Mutation
Opublikowany: 15.03.2017 -
Raising Awareness in a Town with a History of a Rare Disease
Opublikowany: 8.03.2017 -
Helping Rare Disease Patients Navigate the World of Information
Opublikowany: 1.03.2017 -
Overcoming the Challenges of Rare Disease Drug Development
Opublikowany: 22.02.2017 -
Moving Rare Disease Therapies from Hope to Reality
Opublikowany: 15.02.2017 -
Children’s National Launches First-of-its-Kind Rare Disease Center
Opublikowany: 8.02.2017 -
A Common Link in a Group of Rare Diseases Creates an Opportunity for Repurposing
Opublikowany: 1.02.2017 -
Sobi Works to Expand Rare Disease Indications for Its Drugs
Opublikowany: 25.01.2017 -
Why Rare Disease Patients Should Work Together to Address Common Concerns
Opublikowany: 18.01.2017
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.